MDxHealth (NASDAQ:MDXH – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.
Volatility & Risk
MDxHealth has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
Profitability
This table compares MDxHealth and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MDxHealth | -33.46% | N/A | -24.25% |
| Pluri | -2,344.59% | N/A | -82.71% |
Valuation and Earnings
This table compares MDxHealth and Pluri”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MDxHealth | $107.88 million | 0.07 | -$33.52 million | ($0.72) | -0.20 |
| Pluri | $1.02 million | 12.98 | -$23.82 million | ($2.45) | -0.43 |
Pluri has lower revenue, but higher earnings than MDxHealth. Pluri is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current recommendations and price targets for MDxHealth and Pluri, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MDxHealth | 1 | 4 | 1 | 0 | 2.00 |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
MDxHealth presently has a consensus target price of $1.33, suggesting a potential upside of 825.28%. Given MDxHealth’s stronger consensus rating and higher probable upside, equities analysts plainly believe MDxHealth is more favorable than Pluri.
Insider & Institutional Ownership
16.6% of Pluri shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
MDxHealth beats Pluri on 9 of the 13 factors compared between the two stocks.
About MDxHealth
MDxHealth SA (NASDAQ: MDXH) is a molecular diagnostics company focused on helping physicians make more informed decisions in cancer care. The company develops and commercializes genomic and epigenetic tests designed to support cancer detection, diagnosis, prognosis and treatment planning. MDxHealth’s portfolio has primarily centered on prostate cancer. Its ConfirmMDx test analyzes prostate tissue to help identify patients who may have clinically significant cancer despite an initially negative biopsy, while SelectMDx is a urine-based test intended to help assess the likelihood of clinically significant prostate cancer and guide decisions about biopsy.
About Pluri
Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
